Select your baby’s birth date or your due date.
Exclusive distribution in GREECE
Rontis Corporation enters into exclusive distribution agreement with ELPEN Pharmaceutical Co Inc for Rontis Infant Nutrition product line in the Greek Territory
Rontis Corporation S.A. announces that its Swiss subsidiary Rontis AG (Zug, Switzerland) has signed an agreement with ELPEN Pharmaceutical Co Inc (Athens, Greece), for the exclusive distribution of the Rontis Infant Nutrition product line in Greece.
Rontis Corporation produces the Rontamil infant nutrition family of formulas, which so far has been promoted and distributed in the Greek market via its subsidiary entity Rontis Hellas S.A. Rontamil product family is considered as one of the most competitive formulas due to its unique nutritional characteristics.
Following strategic decisions for the presence and the activities of the Rontis subsidiary in south – eastern Europe, the Rontis Infant Nutrition products will be distributed and promoted by ELPEN Pharmaceutical Co Inc. This decision will come into effect on December 1st, 2015.
Both companies’ intention is to enable the establish ment by ELPEN of a focused Pediatric Business Unit within a strong Greek but at the same time multinational pharmaceutical company, which will be in position to promote the complete range of the Rontis Infant Nutrition portfolio, along with the other pediatric products that ELPEN Pharmaceutical Co Inc is already successfully promoting within the specific territory.
Our common target is to avoid disruption in the supply chain and ensure smooth transition to the new reality, which will not affect pharmacies’ or end – customers’ stable supply.
ELPEN Pharmaceutical Co Inc was founded in 1965 and is headquartered in Athens, Greece. Ever since its foundation, ELPEN’s evolution to become the leading Greek pharmaceutical company, was experienced by means of significant milestone events with the passing of each decade.
Rontis Corporation S.A., based in Zug, Switzerland, was established in 1986 and operates 3 manufacturing plants in Europe. It develops and manufactures – among others – a complete range of infant nutrition products, which aside the standard Rontamil 1 – 2 – 3 formulas, it also includes specialty formulas such as Rontamil AC (anti – colic) and Rontamil TR (treating constipation). Rontis vision is to make Rontamil as the infant nutrition product of choice internationally for HCPs and consumers alike.
Through the supply of the complete range of the Rontis infant nutrition product portfolio, ELPEN will further enhance its position to pediatricians, in addition to its existing portfolio and will now be in position to put more focus on the specific segment, in order to drive growth for its entire infant portfolio.
By virtue of this extended exclusive distribution agreement, both Rontis and ELPEN commit to continue contributing to society by serving additional healthcare needs of the market and assisting in improving people’s quality of life.
For further information, please contact Rontis’ Corporate Communication Department at email@example.com.
About Rontis Corporation
Rontis is a privately – held specialty healthcare company, with its headquarters in Zug, Switzerland. It employs over 650 persons worldwide and is organized across 5 major divisions: Medical Devices, Pharmaceuticals, Infant Nutrition, Consumer Healthcare and Healthcare Services. It carries 16 years of experience within the wider Infant Nutrition arena and the respective Division is active in R&D, manufacturing, marketing and international sales of its products. The Infant Nutrition Division believes strongly in the unique combination of pre & probiotics (symbiotics) – even in the standard formula.
For more information, you may visit: www.rontis.com
About ELPEN Pharmaceutical Co Inc
ELPEN was founded in 1965 and is headquartered in Athens, Greece. ELPEN is the leading Greek pharmaceutical company with operations in Greece, Cyprus and Germany. With 655 employees ELPEN currently ranks 1st among Greek companies and 6th overall among 400 companies operating in the Greek pharmaceutical market. ELPEN’s activities include R&D in our 1.000m2 facilities, production, regulatory affairs, marketing, sales, distribution and international business. ELPEN focuses in on- and off-patent products and generics in the areas of CVS, GI, CNS, Antibiotics, Respiratory/Pulmonology, Endocrinology and OTC. We have established partnerships with esteemed companies such as Novartis, Pfizer, Bayer, Takeda, Baxter, Lundbeck, Ferring etc. Our goal is to establish long-term business co-operations with international partners, for our internally developed products, services, technologies and know – how, for the markets abroad. We offer a wide range of Products in the areas of CVS, CNS, GI, Antimicrobials, Respiratory and more.
For more information, you may visit www.elpen.gr